Last10K.com

Livanova Plc (LIVN) SEC Filing 10-Q Quarterly report for the period ending Saturday, September 30, 2017

Livanova Plc

HISTORY TOOLS
CIK: 1639691 Ticker: LIVN


EXHIBIT 99.1
livanovaimage1a02.jpg NEWS RELEASE

LivaNova Reports Third Quarter 2017 Results
 

London, November 2, 2017 –
 LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today reported results for the quarter ended September 30, 2017.

For the third quarter of 2017, worldwide sales were $309.7 million, an increase of 4.9 percent on a reported basis and an increase of 3.1 percent on a constant currency basis, as compared to the same quarter of the previous year. On the basis of U.S. Generally Accepted Accounting Principles (GAAP), third quarter 2017 diluted earnings per share were $0.57. Third quarter 2017 adjusted diluted earnings per share were $0.93.

"We delivered solid sales and earnings performance in the third quarter, with record growth in several of our product areas," said Damien McDonald, LivaNova's Chief Executive Officer. “While we grew in Neuromodulation, results were impacted due to delays in procedures as a result of hurricane-related activity, and also from broad patient deferrals in anticipation of the launch of our newest VNS Therapy® System, SenTivaTM, which received U.S. Food and Drug Administration approval in early October.  Growth in our Cardiac Rhythm Management business was slightly positive, aided by continued demand in Japan for our KORA250® device, even as we explore strategic options for this franchise.  Cardiac Surgery had numerous positive initiatives that coalesced, resulting in mid-single-digit growth in both our cardiopulmonary and heart valve product lines. Due to our strong year-to-date results and momentum across our business, we are increasing our full-year guidance for adjusted diluted earnings per share to $3.30 to $3.45.  We remain on track to meet our other full-year commitments and will continue to take actions that strengthen LivaNova’s position as a focused med-tech innovator dedicated to improving the lives of patients around the world."
  




1
The following information was filed by Livanova Plc (LIVN) on Thursday, November 2, 2017 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Livanova Plc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Livanova Plc.

Continue

Assess how Livanova Plc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Livanova Plc's Definitive Proxy Statement (Form DEF 14A) filed after their 2017 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Rating

Learn More
Bullish Bearish Neutral
Filter by Sentiment:
All
Positive
Negative
Filter by Category:
All
Financial
Revenue
M & A
Other
Filter by Subcategory:
All
Expense
Product
Income
Debt
Geography
Shares
Earnings
Other
Inside Livanova Plc's 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (parenthetical)
Condensed Consolidated Statements Of Cash Flows (unaudited)
Condensed Consolidated Statements Of Comprehensive Income (loss) (unaudited)
Condensed Consolidated Statements Of Income (loss) (unaudited)
Acquisitions
Acquisitions (tables)
Acquisitions - Contingent Consideration (details)
Acquisitions - Contingent Consideration Reconciliation (details)
Acquisitions - Narrative (details)
Acquisitions - Preliminary Purchase Price Allocation (details)
Acquisitions - Purchase Price Composition (details)
Commitments And Contingencies
Commitments And Contingencies (narrative) (details)
Derivatives And Risk Management
Derivatives And Risk Management (amount Of Gain (loss) Recognized In Oci And Income Statement) (details)
Derivatives And Risk Management (derivative Notional Amounts) (details)
Derivatives And Risk Management (fair Value Of Derivative Instruments) (details)
Derivatives And Risk Management (narrative) (details)
Derivatives And Risk Management (tables)
Fair Value Measurements
Fair Value Measurements (assets And Liabilities That Are Measured At Fair Value On A Recurring Basis) (details)
Fair Value Measurements (tables)
Financing Arrangements
Financing Arrangements (long-term Debt Outstanding, Revolving Credit And European Investment Bank Financing Agreement) (details)
Financing Arrangements (tables)
Geographic And Segment Information
Geographic And Segment Information (changes In Carrying Amount Of Goodwill) (details)
Geographic And Segment Information (geographic Areas) (details)
Geographic And Segment Information (segment Info) (details)
Geographic And Segment Information (tables)
Income Taxes
Income Taxes (narrative) (details)
Investments
Investments (cost-method Investments) (details)
Investments (equity Method Investments) (details)
Investments (tables)
Net Income (loss) Per Share
Net Income (loss) Per Share (narrative Of Antidilutive Securities Excluded From Computation Of Earnings Per Share) (details)
Net Income (loss) Per Share (schedule Of Earnings Per Share, Basic And Diluted) (details)
Net Income (loss) Per Share (tables)
New Accounting Pronouncements
New Accounting Pronouncements (details)
Product Remediation Liability
Product Remediation Liability (details)
Product Remediation Liability (tables)
Restructuring
Restructuring (accrual Detail) (details)
Restructuring (narrative) (details)
Restructuring (restructuring Expense By Segment) (details)
Restructuring (tables)
Stock-based Incentive Plan (compensation Expense) (details)
Stock-based Incentive Plan (executed Agreements) (details)
Stock-based Incentive Plan (tables)
Stock-based Incentive Plans
Stockholders' Equity
Stockholders' Equity (comprehensive Income) (details)
Stockholders' Equity (tables)
Supplemental Financial Information
Supplemental Financial Information (summary Of Accounts Receivable) (details)
Supplemental Financial Information (summary Of Accrued Liabilities) (details)
Supplemental Financial Information (summary Of Inventory) (details)
Supplemental Financial Information (summary Of Other Long-term Assets) (details)
Supplemental Financial Information (summary Of Other Long-term Liabilities) (details)
Supplemental Financial Information (summary Of Prepaid Expenses And Other Assets) (details)
Supplemental Financial Information (tables)
Unaudited Condensed Consolidated Financial Statements
Unaudited Condensed Consolidated Financial Statements (narrative) (details)
Unaudited Condensed Consolidated Financial Statements (policies)

Material Contracts, Statements, Certifications & more

Livanova Plc provided additional information to their SEC Filing as exhibits

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 32.1: Section 1350 Certification
Ticker: LIVN
CIK: 1639691
Form Type: 10-Q Quarterly Report
Accession Number: 0001639691-17-000097
Submitted to the SEC: Thu Nov 02 2017 1:14:57 PM EST
Accepted by the SEC: Thu Nov 02 2017
Period: Saturday, September 30, 2017
Industry: Electromedical And Electrotherapeutic Apparatus

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/livn/0001639691-17-000097.htm